Scleroderma Symptoms, Types, Causes, Risk Factors | NIAMS Localized scleroderma only affects the skin and the structures directly under the skin Systemic scleroderma, also called systemic sclerosis, affects many systems in the body This is the more serious type of scleroderma and can damage your blood vessels and internal organs, such as the heart, lungs, and kidneys
Systemic sclerosis (scleroderma) - BMJ Best Practice Systemic sclerosis (scleroderma) is a non-contagious, chronic, multi-system disease Initial symptoms are non-specific and include fatigue, vague musculoskeletal complaints, diffuse swelling of hands, and Raynaud's phenomenon Aetiology and pathogenesis are unknown Disease course is variable, but the condition rarely subsides spontaneously
Scleroderma: Diagnosis, Treatment, and Steps to Take Treatment of Scleroderma Your treatment depends on the type of scleroderma you have, your symptoms, and which tissues and organs are affected Treatment can help control the symptoms and limit damage Your doctor may recommend medications, including: Anti-inflammatory medications to manage pain and reduce swelling
Esclerodermia | Temas de salud | NIAMS La esclerodermia es una enfermedad que causa parches de piel dura y gruesa, pero también puede dañar los vasos sanguíneos y otros órganos Conozca los factores de riesgos y las causas de esta enfermedad de la piel
Limited cutaneous systemic sclerosis - BMJ Best Practice Systemic sclerosis (a type of scleroderma) is an auto-immune connective tissue disease characterised by the production of auto-antibodies (e g , antinuclear antibody, anti-centromere antibody, and anti-topoisomerase I antibody) and the overproduction of collagen, which causes fibrosis of the skin and organs as well as vasculopathy with Raynaud's phenomenon and obliteration of blood vessels
Scleroderma: Research Resources - National Institute of Arthritis and . . . Understanding why scleroderma can affect African Americans more severely Evaluating how immunosuppressant and other medications can be used to help manage the symptoms and complications of scleroderma, particularly pulmonary complications Exploring the many factors that lead to fibrosis to see if their development can be blocked
Symptoms, diagnosis and treatment - BMJ Best Practice PM Scl syndrome is characterized by overlapping features of scleroderma and polymyositis, PM Scl antibody, Raynaud phenomenon, tendon inflammation, and interstitial lung disease Treatment of overlap syndromes is tailored to the active clinical manifestations and ranges from supportive therapy to cytotoxic immunosuppressive regimens
Scleroderma, Fibrosis, and Autoinflammatory Disease Program It is a heterogenous and complex disease that can be categorized as localized scleroderma (morphea) and systemic scleroderma While etiology of scleroderma is poorly understood, abnormal vasculature, inflammation, and fibrosis are main characteristics of the disease with diverse clinical manifestations (e g Raynaud’s phenomenon, digital ulcers, fibrosis in skin and internal organs)
Calendario